Vascular endothelial growth factor gene therapy - HSCI
Alternative Names: Neovasculgen; PI-VEGF165; VEGF gene therapy - HSCILatest Information Update: 28 Sep 2018
Price :
$50 *
At a glance
- Originator Human Stem Cells Institute
- Class Gene therapies; Ischaemic heart disorder therapies; Vascular disorder therapies
- Mechanism of Action Angiogenesis inducing agents; Vascular endothelial growth factor A expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Peripheral arterial disorders
- No development reported Diabetic foot ulcer
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for clinical-Phase-Unknown development in Diabetic-foot-ulcer in Russia (IM, Injection)
- 01 Aug 2015 Clinical trials in Diabetic foot ulcer in Russia (IM)
- 05 Feb 2015 Human Stem Cell Institute plans a phase I/II trial for Peripheral nerve injuries (Adjuvant therapy) in Russia (NCT02352649)